Docteur JEAN-CLAUDE MASSON

• Caractérisation démographique et génétique de trois races bovines créoles colombiennes

  2010

  Doctorant·e : Carlos Lucero

  Biologie et agronomie🎓 Rennes, Agrocampus Ouest

Source theses.fr — signal de direction d'équipe / statut PU-PH (à confirmer via le site universitaire).

Bibliographie

• Les faits constitutifs de concurrence déloyale

  2015

  CongrèsLa propriété intellectuelle dans les droits du marché et de la rivalité concurrentielle

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Lieu de consultation

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

Prendre rendez-vous & contact

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Articles de presse (3)

Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).

• Orbey | Anniversaire. Les 90 ans de Jean-Claude Masson - DNA

  📰 DNA · 06/02/2024

  <a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9YRVV5enlNVWJHVUxrNVpUSkwyV01QcHhkbEJpQXlKM0pMOEVLbzJYR2xqY0RDR2l4cFFuR2ljUkxUNV92U0RyX3ltc0F0Mzk5cG5adVhoZ2ZEcGtXR19BWFpQZlhwa3hZbXBsNnlhZnVfLUxEbjFJMEFn?oc=5" target="_blank">Orbey | Anniversaire. Les 90 ans de Jean-Claude Masson</a>&nbsp

• Un médecin birman - Revue Esprit

  📰 Revue Esprit · 06/01/2023

  <a href="https://news.google.com/rss/articles/CBMif0FVX3lxTE9BdTBNbDl3SmtEUEJJZzRiZWZ3SUZaT3p6MHc4Z3piYVlYaTNWVmc2YTEtNnNWb3YzRHRFTGVHdUZhdlBJZElCb21VeXZuQUU3aTVZS0NEZ2laTHVuaW5tMUlvSWJtZDA2UDdBNjR2MHJvWjlRMVBham9OT013am8?oc=5" target="_blank">Un médecin birman</a>&nbsp;&nbsp;<font color="#6f6f6f">R

• Arcade recherche des bénévoles pour ses missions - Ouest-France

  📰 Ouest-France · 22/10/2016

  <a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxQNlFrY3M2RHZheFNiWi1LS0lWamRLbDV2QW1XMVlnQUFGYWVZSE5RLTFxVFVaVzRwSTN1RDVoYXh1SUYzQjcwWE1KNktsSVE0aERGNTBTQmw5QkotdWxSaHprOHY4LTNNVVFNaFpkOF9nZzZiRFRkTG50anZHelhyVUJQaU0yem9VWkdYU2xpLUx2TnktZ1hZcXRGOW5iMFd2YUxsV0xuNEdyMVV3MDhHV3lOM0xHQQ?oc=

Top publications · les plus citées

• 1

  The gout epidemic in French Polynesia: a modelling study of data from the Ma'i u'u epidemiological survey

  The Lancet. Global health · 2024

  📚 26 citations🎯 RCR 7.58Top 4% NIH🔓 Open Access📄 PDF gratuit ↗
• 2

  A single-centre experience of 29 total ankle replacement in haemophiliac patients: Therapeutic management, factor consumption and cost

  Haemophilia : the official journal of the World Federation of Hemophilia · 2024

  📚 4 citations🎯 RCR 2.37Top 22% NIH🔓 Open Access📄 PDF gratuit ↗

  Lire l'abstract Crossref ↓

  AbstractIntroductionIn patients with haemophilia, repeated bleeding in large joints leads to chronic haemophilic arthropathy, a rare disease that can be managed surgically with ankle arthrodesis or with total ankle replacement (TAR). TAR has been reported to provide good surgical results in the medium/long‐term and allow preservation of joint mobility but the medical therapeutic management of the patients has not been described.AimTo describe the medical therapeutic management of TAR.MethodsAll patients with haemophilia A/B, with haemophilic ankle arthropathy, and who underwent TAR between April 2006 and October 2019 were retrospectively included. Factor consumption, perioperative and early complications, volume of blood lost, and orthopaedic data were collected.ResultsA total of 25 patients underwent 29 TAR (mean age was 44.7 years [range: 26–65]). In the 17 patients with HA without history of anti‐FVIII inhibitor, the mean ± SD consumption the day of surgery was 116 ± 16 UI/kg when clotting factors were administered by continuous infusion, 106 ± 13 UI/kg when SHL factors were administered by bolus infusion, and 75 ± 22 UI/kg when EHL factors were administered by bolus infusion. During hospitalisation, the mean factor cost was €38,073 (83.7% of the total cost of surgery). Mean blood loss was significantly lower in patients treated with tranexamic acid (164 mL, range: 40–300) than in those not (300 mL, range: 70–800; p = .01). Six patients had haematoma. The 10‐year survival free of any prosthesis removal/arthrodesis was estimated to be 92.2% (95% CI [83; 100]).ConclusionThe medical therapeutic management of TAR is complex, carried out by a multidisciplinary team but effective in avoiding the occurrence of complications.

Publications scientifiques (2) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Partager cette fiche